

Clinical Practice Guideline: Lipid Screening

Date of Implementation: June 19, 2014

Product: Specialty

GUIDELINES

Practitioners, as appropriate to their education, training, experience, and scope of practice, can provide valuable screening for common risk factors and health conditions. The guidelines provided within this American Specialty Health – Specialty (ASH) Clinical Practice Guideline focus on screening procedures for lipids.

Among portal of entry practitioners, screening at risk and/or symptomatic patients for lipid imbalances is considered best practice. Providing a direct intervention (e.g., lifestyle and/or dietary changes) for patients for whom the screening results indicated a need for intervention, will depend upon the practitioner’s education, training, experience, and scope of practice. In the absence of such a direct intervention, providing a referral intervention (e.g., to the patient’s medical physician) is considered necessary. The screenings described in this guideline may be outside the education, training, experience, or scope of some practitioner types. In the context of best practices for these practitioners, a level of awareness that risk factors and/or signs/symptoms of the above conditions are present is required and a subsequent referral for appropriate evaluation is necessary and within the purview of all.

INTRODUCTION

Health issues identified through appropriate screening provide patients with earlier detection and increase the likelihood of successful treatment. In some cases, the detrimental effects of a disease or health condition can be mitigated or possibly reversed with appropriate early detection and care (e.g., Type 2 diabetes or cardiovascular disease). Applicable recommendations for the preventive health screenings covered in this policy are based on the United States Preventive Services Task Force (USPSTF), as well as other evidence-based guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Practice Guidelines for blood cholesterol.

A comprehensive review of the USPSTF evidence rating process can be found in the ASH clinical practice guideline *Preventive Care Services (CPG 140 – S)* or at the USPSTF website: <http://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions>

LIPID SCREENING

Lipid disorders, also called dyslipidemias, are abnormalities of lipoprotein metabolism and include elevated total cholesterol (TC), low density lipoprotein (LDL-C), or triglycerides (TG), or deficient levels of high-density lipoprotein (HDL-C). Dyslipidemias are acquired

or familial. Dyslipidemia is a modifiable risk factor for coronary artery disease. Risk factors for dyslipidemia include an atherogenic diet (diet high in saturated fatty acids, cholesterol, and sodium), diet high in added sugars, physical inactivity, obesity, abdominal obesity, metabolic syndrome, hypertension, genetic factors, age, and male sex (Chou, 2022).

ASSESSING LIPID LEVELS

Fasting or non-fasting plasma lipid levels are recommended for adults aged 20 and older to estimate the risk of atherosclerotic cardiovascular disease (ASCVD) and obtain baseline LDL-C levels. If the initial non-fasting lipid profile has a triglyceride level of 400mg/dL or higher, a repeat fasting lipid profile should be performed to assess fasting triglyceride levels and baseline LDL-C. Lipid screening should be performed every 4 to 6 years for adults without cardiovascular disease.

The ranges for lipid panels are below. Individual goals will depend on the number of risk factors for heart disease, age, and other factors.

Total cholesterol in adults:

- Normal: less than 200mg/dL
- Borderline high: 200 to 239 mg/dL
- High: At or above 240mg/dL

LDL-C

- Optimal: less than 100mg/dL
- Near optimal: 100 to 129mg/dL
- Borderline high: 130 to 159 mg/dL
- High: 160 to 189 mg/dL
- Very high: 190 gm/dL or greater

HDL-C: goal is above 40mg/dL. Above 60 mg/dL is considered cardioprotective

Triglycerides

- Normal: less than 150 mg/dL
- Borderline high: 150 to 199 mg/dL
- High: 200 to 499 mg/dL
- Very high: above 500 mg/dL

Primary hypercholesterolemia is defined as:

- LDL-C 160-189mg/dL [4.1-4.8 mmol/L]
- Non-HDL-C 190-219 mg/dL [4.9-5.6 mmol/L]

ASCVD Risk Enhancers:

- Family history of premature ASCVD
- Persistently elevated LDL-C of ≥ 160 mg/dL (≥ 4.1 mmol/L)
- Chronic kidney disease
- Metabolic syndrome
- Conditions specific to women (e.g., preeclampsia, premature menopause)
- Inflammatory diseases (especially rheumatoid arthritis, psoriasis, HIV)
- Ethnicity (e.g., South Asian ancestry)
- Lipid/Biomarkers
 - Persistently elevated triglycerides (≥ 175 mg/dL, (≥ 2.0 mmol/L))
- In selected individual if measured:
 - Hs-CRP ≥ 2.0 mg/L
 - Lp(a) levels > 50 mg/dL or > 125 nmol/L
 - apoB ≥ 130 mg/dL
 - Ankle-brachial index (ABI) < 0.9

A separate USPSTF (2023) recommendation statement found insufficient evidence to assess the balance of benefits and harms of screening for lipid disorders in asymptomatic children and adolescents who are 20 years or younger.

INTERVENTIONS

Therapeutic Lifestyle Change (TLC). The National Heart, Lung and Blood Institute of the National Institutes of Health recommends a program of TLC to regulate dyslipidemia. The main components of TLC* are:

- Reduced dietary saturated fat (to compose $< 7\%$ of total caloric intake);
- Increased plant sterols (add 2 g/day) and soluble fiber (add 5-10 g/day) to lower LDL;
- Reduce dietary cholesterol to less than 200 mg/day
- 25–35 percent of daily calories from total fat (includes saturated fat calories)
- Weight reduction for patients with obesity or overweight;
- Increased physical activity (at least 30 minutes of a moderate intensity physical activity, such as brisk walking, on most, and preferably all, days of the week.

*Lifestyle modifications (diet and physical activity) are appropriate initial therapies for most patients with some achieving significant lipid level reductions from dietary changes alone.

According to the ACC/AHA guidelines, “lifestyle modification (i.e., adhering to a heart healthy diet, regular exercise habits, avoidance of tobacco products, and maintenance of a healthy weight) remains a critical component of health promotion and ASCVD risk reduction, both prior to and in concert with the use of cholesterol-lowering drug therapies.”

Drug Therapy is considered to be effective for most people with a history of heart disease in improving lipid profiles. Medications may be needed to achieve therapeutic goals. However, treatment must consider the risks involved, costs, and patient preferences.

The 2022 USPSTF recommendation for statin use for the primary prevention of cardiovascular disease in adults is as follows:

Population	Recommendation	Grade
Adults aged 40 to 75 years who have 1 or more cardiovascular risk factors and an estimated 10-year cardiovascular disease (CVD) risk of 10% or greater	The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater.	<u>B</u>
Adults aged 40 to 75 years who have 1 or more cardiovascular risk factors and an estimated 10-year CVD risk of 7.5% to less than 10%	The USPSTF recommends that clinicians selectively offer a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 7.5% to less than 10%. The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater.	<u>C</u>
Adults 76 years and older	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older.	<u>I</u>

These recommendations apply to adults 40 years or older without a history of known CVD and who do not have signs and symptoms of CVD. These recommendations do not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia. These populations are at very high risk for CVD, and considerations on the use of statins in these populations can be found in other organizations' guidelines.

The American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations may be used to estimate 10-year risk of CVD. The estimator has separate equations based on sex and for Black persons and non-Black persons, which include the risk factors of age, cholesterol levels, systolic blood pressure level, antihypertension

treatment, presence of diabetes, and smoking status, and focuses on hard clinical outcomes (myocardial infarction and death from coronary heart disease; ischemic stroke and stroke-related death) as the outcomes of interest. Age is one of the strongest risk factors for CVD, and the 10-year CVD event risk estimated by the ACC/AHA risk estimator is heavily influenced by increasing age. The risk prediction equations generally show higher risk for Black persons than White persons. The USPSTF recognizes that race is a social construct, and it is an imperfect proxy for social determinants of health and the effects of structural racism. Concerns about calibration of the Pooled Cohort Equations exist, with many external validation studies showing overprediction in broad populations (men and women across racial and ethnic groups). Limited evidence also suggests underprediction in disadvantaged communities that could lead to underutilization of preventive therapies. Clinicians should recognize that predictions of 10-year CVD events using the Pooled Cohort Equations are estimates.

The higher a person's 10-year risk of a CVD event, the greater the chance of benefit from statin use. Thus, the expected benefit of statin therapy for persons with a 10-year CVD risk of 10% or greater exceeds the expected benefit for persons with a 10-year CVD risk of 7.5% to less than 10%. Clinicians should discuss with patients the potential risk of having a CVD event and the expected benefits and harms of statin use. For patients with an estimated 10-year CVD risk of 10% or greater and who smoke or have dyslipidemia, diabetes, or hypertension, the USPSTF recommends that clinicians prescribe a statin once the rationale has been explained and the patient agrees to take a statin. For patients with an estimated 10-year CVD risk of 7.5% to less than 10% (and who have ≥ 1 of the risk factors noted above), clinicians may selectively offer a statin, taking patient values and preferences into account. Patients in this estimated risk range who place a higher value on the potential benefits than on the potential harms and inconvenience of taking a daily medication may choose to initiate a statin.

Given that participants in clinical trials of statin therapy were enrolled based on the presence of 1 or more CVD risk factors, and that the magnitude of benefit of statin use is proportional to a person's estimated 10-year CVD risk, the USPSTF recommends that clinicians evaluate both the presence of CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking) as well as estimated 10-year risk of CVD in determining which persons should initiate use of statins.

Periodic assessment of cardiovascular risk factors from ages 40 to 75 years, including measurement of total cholesterol, LDL-C, and HDL-C levels, is required to implement this recommendation. The optimal intervals for cardiovascular risk assessment are uncertain. Based on other guidelines and expert opinion, reasonable options include annual assessment of blood pressure and smoking status and measurement of lipid levels every 5 years. Shorter intervals may be useful for persons whose risk levels are close to those warranting therapy, and longer intervals are appropriate for persons who are not at increased risk and have repeatedly normal levels.

The 4 groups identified in the ACC/AHA guidelines for major statin benefit are:

1. Individuals with any form of clinical ASCVD
2. Individuals with primary LDL levels of ≥ 190 mg per dL
3. Individuals with diabetes mellitus aged 40-75 years with LDL levels of 70-189mg per dL
4. Individuals without clinical ASCVD or diabetes who are 40 to 75 years of age with LDL-C 70- 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher

An easy reference guide summarizing the ACC/AHA 2019 recommendations for ASCVD risk assessment and treatment is available in the form of a flow chart online at: <https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000000678>.

The USPSTF concludes there are limited data directly comparing the effects of different statin intensities on health outcomes. A majority of the trials reviewed by the USPSTF used moderate-intensity statin therapy. Based on available evidence, use of moderate-intensity statin therapy seems reasonable for the primary prevention of CVD in most persons.

The 2018 and 2019 ACC/AHA guidelines define cardiovascular risk categories as high (10-year risk of cardiovascular events $\geq 20\%$), intermediate (10-year risk of cardiovascular events $\geq 7.5\%$ to $<20\%$), and borderline (10-year risk of cardiovascular events 5% to $<7.5\%$). The guidelines recommend initiation of statin therapy in persons at intermediate or high risk and a risk discussion for persons at borderline risk and recommend consideration of risk enhancers to refine risk assessments based on the Pooled Cohort Equations and inform decision-making for persons at intermediate and borderline risk. These risk enhancers include family history of early coronary heart disease, presence of chronic kidney disease, metabolic syndrome, preeclampsia, premature menopause, inflammatory diseases, HIV, and South Asian ancestry.

For primary prevention, the 2020 US Department of Veterans Affairs/US Department of Defense Clinical Practice Guideline recommends initiation of a moderate-dose statin in persons with an estimated 10-year cardiovascular risk of 12% or greater and shared decision-making for persons with an estimated 10-year cardiovascular risk of 6% to 12%.

PRACTITIONER SCOPE AND TRAINING

Practitioners should practice only in the areas in which they are competent based on their education, training, and experience. Levels of education, experience, and proficiency may vary among individual practitioners. It is ethically and legally incumbent on a practitioner to determine where they have the knowledge and skills necessary to perform such services and whether the services are within their scope of practice.

It is best practice for the practitioner to appropriately render services to a patient only if they are trained, equally skilled, and adequately competent to deliver a service compared to others trained to perform the same procedure. If the service would be most competently

delivered by another health care practitioner who has more skill and training, it would be best practice to refer the patient to the more expert practitioner.

Best practice can be defined as a clinical, scientific, or professional technique, method, or process that is typically evidence-based and consensus driven and is recognized by a majority of professionals in a particular field as more effective at delivering a particular outcome than any other practice (Joint Commission International Accreditation Standards for Hospitals, 2020).

Depending on the practitioner's scope of practice, training, and experience, a patient's condition and/or symptoms during examination or the course of treatment may indicate the need for referral to another practitioner or even emergency care. In such cases it is essential for the practitioner to refer the patient for appropriate co-management (e.g., to their primary care physician) or if immediate emergency care is warranted, to contact 911 as appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice guideline for information.

PRACTITIONER & MEMBER RESOURCES

Publicly available resources can be found at:

- USPSTF Screening Recommendations
<https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations>
- 10 Year Risk Calculator for Atherosclerotic Cardiovascular Disease
<http://tools.acc.org/ASCVD-Risk-Estimator/>
- National Institutes of Health Medline Plus. Cholesterol:
<http://www.nlm.nih.gov/medlineplus/cholesterol.html#cat57>
- American Heart Association. Cholesterol home page:
<https://www.heart.org/en/health-topics/cholesterol>
- HealthFinder.gov. Get Your Cholesterol Checked:
<http://www.healthfinder.gov/HealthTopics/Category/doctor-visits/screening-tests/get-your-cholesterol-checked>

REFERENCES

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in *Circulation*. 2019 Sep 10;140(11):e649-e650] [published correction appears in *Circulation*. 2020 Jan 28;141(4):e60] [published correction appears in *Circulation*. 2020 Apr 21;141(16):e774]. *Circulation*. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678

- 1 Centers for Disease Prevention and Control. Cholesterol. Retrieved on February 21, 2025
- 2 from <https://www.cdc.gov/cholesterol/>
- 3
- 4 Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular
- 5 Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force
- 6 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022
- 7 Aug. (Evidence Synthesis, No. 219.) Available from:
- 8 <https://www.ncbi.nlm.nih.gov/books/NBK583661/>
- 9
- 10 Department of Veterans Affairs. Department of Defense. VA/DoD Clinical Practice
- 11 Guideline for the Management of Dyslipidemia for Cardiovascular Risk Reduction.
- 12 2020. Retrieved February 21, 2025 from
- 13 [https://www.healthquality.va.gov/guidelines/CD/lipids/VADoDDyslipidemiaCPG508](https://www.healthquality.va.gov/guidelines/CD/lipids/VADoDDyslipidemiaCPG5087212020.pdf)
- 14 [7212020.pdf](https://www.healthquality.va.gov/guidelines/CD/lipids/VADoDDyslipidemiaCPG5087212020.pdf)
- 15
- 16 Grundy SM, Stone NJ, Bailey AL, et al. 2018
- 17 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
- 18 Guideline on the Management of Blood Cholesterol: A Report of the American College
- 19 of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 20 [published correction appears in Circulation. 2019 Jun 18;139(25):e1182-
- 21 e1186]. Circulation. 2019;139(25):e1082-e1143.
- 22 doi:10.1161/CIR.0000000000000625
- 23
- 24 Helfand M, Carson S. *Screening for Lipid Disorders in Adults: Selective Update of 2001*
- 25 *US Preventive Services Task Force Review*. Rockville (MD): Agency for Healthcare
- 26 Research and Quality (US); June 2008
- 27
- 28 Joint Commission International. Joint Commission International Accreditation Standards
- 29 for Hospitals (7th ed.): Joint Commission Resources; 2020
- 30
- 31 Lozano P, Henrikson NB, Dunn J, et al. Lipid Screening in Childhood and Adolescence
- 32 for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for
- 33 the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare
- 34 Research and Quality (US); August 2016
- 35
- 36 Murphy SL, Xu J, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final Data for
- 37 2018. Natl Vital Stat Rep. 2021;69(13):1-83
- 38
- 39 NIH National Heart, Lung, and Blood Institute. Therapeutic Lifestyle Changes (TLC) To
- 40 Lower Cholesterol. Retrieved on January 19, 2024 from
- 41 [https://www.nhlbi.nih.gov/education/TLC-Therapeutic-Lifestyle-Changes-Lower-](https://www.nhlbi.nih.gov/education/TLC-Therapeutic-Lifestyle-Changes-Lower-Cholesterol#:~:text=What%20is%20the%20TLC%20Program,a%20heart%2Dhealth%20eating%20regimen)
- 42 [Cholesterol#:~:text=What%20is%20the%20TLC%20Program,a%20heart%2Dhealth](https://www.nhlbi.nih.gov/education/TLC-Therapeutic-Lifestyle-Changes-Lower-Cholesterol#:~:text=What%20is%20the%20TLC%20Program,a%20heart%2Dhealth%20eating%20regimen)
- 43 [y%20eating%20regimen](https://www.nhlbi.nih.gov/education/TLC-Therapeutic-Lifestyle-Changes-Lower-Cholesterol#:~:text=What%20is%20the%20TLC%20Program,a%20heart%2Dhealth%20eating%20regimen)

1 Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary
 2 prevention: a meta-analysis of 11 randomized controlled trials involving 65,229
 3 participants. *Arch Intern Med*. 2010;170(12):1024-1031.
 4 doi:10.1001/archinternmed.2010.182

6 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment
 7 of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of
 8 the American College of Cardiology/American Heart Association Task Force on
 9 Practice Guidelines [published correction appears in *Circulation*. 2014 Jun 24;129(25
 10 Suppl 2):S46-8] [published correction appears in *Circulation*. 2015 Dec
 11 22;132(25):e396]. *Circulation*. 2014;129(25 Suppl 2):S1-S45.
 12 doi:10.1161/01.cir.0000437738.63853.7a

14 U.S. Preventive Services Task Force. *Lipid Disorders in Children and Adolescents:*
 15 *Screening*. July 2023. Retrieved February 21, 2025 from
 16 [https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening)
 17 [disorders-in-children-screening](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening)

19 U.S. Preventive Services Task Force. *Statin Use for the Primary Prevention of*
 20 *Cardiovascular Disease in Adults: Preventive Medication*. August 2022. Retrieved on
 21 February 21, 2025 from
 22 [https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication)
 23 [adults-preventive-medication](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication)